Neda Cramer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neda Cramer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rotraut Mössner
Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Göttingen
9 shared publications - Michael Peter Schön
Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Göttingen
8 shared publications - Christian Kromer
Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Göttingen
3 shared publications - Claudia Günther
Department of Dermatology, Faculty of Medicine and University Hospital Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany
3 shared publications - Dagmar Wilsmann-Theis
Center for Skin Diseases Department of Dermatology and Allergology University Hospital Bonn Bonn Germany
3 shared publications Johannes Mohr
Department of Dermatology Venereology and Allergology University Medical Center Göttingen, Germany
3 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1591-1593
Erfolgreiche Behandlung einer palmoplantaren Pustulose mit topischem Ruxolitinib
- 11 December 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1591-1593
Open AccessErfolgreiche Behandlung einer palmoplantaren Pustulose mit topischem Ruxolitinib
- Open Access
- 18 October 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (3) , 414-416
Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa
- 18 October 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (3) , 414-416
Open AccessBimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa
- Open Access
- 8 September 2025
- Published by Dermsquared in Dermatology Online Journal
- Vol. 31 (4)
Successful treatment of severe acrodermatitis continua of Hallopeau with guselkumab
- 8 September 2025
- Published by Dermsquared in Dermatology Online Journal
- Vol. 31 (4)
Open AccessSuccessful treatment of severe acrodermatitis continua of Hallopeau with guselkumab
- Open Access
- 23 August 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1591-1593
Successful treatment of palmoplantar pustulosis with topical ruxolitinib
- 23 August 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1591-1593
Open AccessSuccessful treatment of palmoplantar pustulosis with topical ruxolitinib
- Open Access
- 8 April 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (4) , 449-464
Anamnese, klinische Merkmale, Therapie und patientenberichtete Ergebnisse bei Lichen ruber mucosae: Eine Querschnittsstudie
Zusammenfassung: Hintergrund: Der Lichen ruber mucosae (LRM) ist eine chronische entzündliche Erkrankung. Der Weg des Patienten mit der Krankheit kann schwierig sein, da die Diagnosestellung und Therapie eine Herausforderung darstellen. Patienten und Methodik: In dieser Querschnittsstudie wurden bei insgesamt 72 Patienten mit LRM, die zwischen 02/2022 und 07/2023 in den dermatologischen Abteilungen von sechs deutschen Universitätskliniken behandelt wurden, eine Vielzahl von Charakteristika zum Krankheitsverlauf erfasst und ausgewertet. Ergebnisse: Zwischen dem Auftreten der Symptome und der Diagnosestellung lagen im Durchschnitt 18,1 Monate. Bis zur korrekten Diagnosestellung wurden durchschnittlich 3,1 verschiedene Ärzte der gleichen oder anderer Fachrichtungen konsultiert. 28,1% der Patienten hatten auch eine Hautbeteiligung. Therapeutisch erhielten 68% der Patienten mindestens ein systemisches Medikament. Sowohl topische (90%, 65/72) als auch systemische (oral, 50%, 36/72; intravenös, 33%, 24/72) Glukokortikoide wurden am häufigsten eingesetzt. Systemische Medikamente wurden am häufigsten wegen Unwirksamkeit abgesetzt (46%, 50/110). Die Zufriedenheit mit der Behandlung war bei intravenösen und topischen Glukokortikoiden am höchsten (mittlere bis hohe Zufriedenheit: 59% bzw. 36%) und bei Retinoiden mit 8% am niedrigsten. Schlussfolgerungen: Die Ergebnisse dieser Studie deuten darauf hin, dass das diagnostische Bewusstsein der Ärzte möglicherweise unzureichend ist und dass ein Bedarf an wirksamen systemischen Therapien besteht.
- 8 April 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (4) , 449-464
Open AccessAnamnese, klinische Merkmale, Therapie und patientenberichtete Ergebnisse bei Lichen ruber mucosae: Eine Querschnittsstudie
Zusammenfassung: Hintergrund: Der Lichen ruber mucosae (LRM) ist eine chronische entzündliche Erkrankung. Der Weg des Patienten mit der Krankheit kann schwierig sein, da die Diagnosestellung und Therapie eine Herausforderung darstellen. Patienten und Methodik: In dieser Querschnittsstudie wurden bei insgesamt 72 Patienten mit LRM, die zwischen 02/2022 und 07/2023 in den dermatologischen Abteilungen von sechs deutschen Universitätskliniken behandelt wurden, eine Vielzahl von Charakteristika zum Krankheitsverlauf erfasst und ausgewertet. Ergebnisse: Zwischen dem Auftreten der Symptome und der Diagnosestellung lagen im Durchschnitt 18,1 Monate. Bis zur korrekten Diagnosestellung wurden durchschnittlich 3,1 verschiedene Ärzte der gleichen oder anderer Fachrichtungen konsultiert. 28,1% der Patienten hatten auch eine Hautbeteiligung. Therapeutisch erhielten 68% der Patienten mindestens ein systemisches Medikament. Sowohl topische (90%, 65/72) als auch systemische (oral, 50%, 36/72; intravenös, 33%, 24/72) Glukokortikoide wurden am häufigsten eingesetzt. Systemische Medikamente wurden am häufigsten wegen Unwirksamkeit abgesetzt (46%, 50/110). Die Zufriedenheit mit der Behandlung war bei intravenösen und topischen Glukokortikoiden am höchsten (mittlere bis hohe Zufriedenheit: 59% bzw. 36%) und bei Retinoiden mit 8% am niedrigsten. Schlussfolgerungen: Die Ergebnisse dieser Studie deuten darauf hin, dass das diagnostische Bewusstsein der Ärzte möglicherweise unzureichend ist und dass ein Bedarf an wirksamen systemischen Therapien besteht.
- Open Access
- 16 February 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (4) , 449-462
History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross‐sectional study
Summary: Background and Objectives: Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging. Patients and Methods: In this cross‐sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023. Results: On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%. Conclusions: This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.
- 16 February 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (4) , 449-462
Open AccessHistory, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross‐sectional study
Summary: Background and Objectives: Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging. Patients and Methods: In this cross‐sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023. Results: On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%. Conclusions: This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.
- Open Access
- 8 January 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (1) , 93-96
Therapie eines schweren gemischten Handekzems und generalisierten Ekzems mit dem JAK‐Inhibitor Upadacitinib
- 8 January 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (1) , 93-96
Open AccessTherapie eines schweren gemischten Handekzems und generalisierten Ekzems mit dem JAK‐Inhibitor Upadacitinib
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Drug Survival in the Treatment of Mucosal Lichen Planus: A Retrospective Multicenter Study
Background and Objectives: Mucosal lichen planus (LP) is a rare chronic inflammatory skin disease. Its treatment is difficult and comparative data on the sustainability of different drugs are lacking. We aimed to retrospectively assess patient and disease characteristics and analyze drug survival rates in the treatment of mucosal LP under real‐world conditions. Patients and Methods: Our retrospective study included patients with mucosal LP treated systemically in the dermatology departments of five German University Medical Centers between 01/2005 and 03/2022. Patient and disease characteristics and treatment responses were evaluated. Drug survival from systemic therapies was assessed by Kaplan–Meier analysis and multivariate regression. Results: Overall, 281 patients with a total of 407 treatment courses were identified. The overall median drug survival was 5.0 months (conventional drugs: 5.0 months vs. novel drugs [biologicals and Janus kinase inhibitors]: 17.0 months, p = 0.029). Among conventional drugs, median drug survival was numerically the highest for methotrexate (13.0 months), followed by mycophenolate mofetil (12.0 months); hydroxychloroquine (9.0 months); acitretin and cyclosporine (6.0 months each); azathioprine, dapsone, and other retinoids (5.0 months each); and finally glucocorticoids (2.0 months). Among novel drugs, median drug survival was numerically the highest in TNF‐α blockers and IL‐17 antagonists (median: 21.0 and 17.0 months, respectively), while median drug survival for Janus kinase inhibitors has not yet been reached. Altogether, the outcomes were documented in 68.6% of cases, with excellent (33.5%), partial (34.5%) or nonresponse (32.0%) in one‐third of cases each. The group of novel therapies comprising biologicals and Janus kinase inhibitors was significantly more effective than the group of conventional drugs (excellent response: 66.7%, 8/12 vs. 32.1%, 83/258; P = 0.013, χ 2 ‐test). Conclusions: In addition to glucocorticoids, cyclosporine, mycophenolate mofetil, and methotrexate (plus hydroxychloroquine), biologicals and Janus kinase inhibitors in particular seem to be therapeutic options for the treatment of mucosal LP, which is worth investigating further.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessDrug Survival in the Treatment of Mucosal Lichen Planus: A Retrospective Multicenter Study
Background and Objectives: Mucosal lichen planus (LP) is a rare chronic inflammatory skin disease. Its treatment is difficult and comparative data on the sustainability of different drugs are lacking. We aimed to retrospectively assess patient and disease characteristics and analyze drug survival rates in the treatment of mucosal LP under real‐world conditions. Patients and Methods: Our retrospective study included patients with mucosal LP treated systemically in the dermatology departments of five German University Medical Centers between 01/2005 and 03/2022. Patient and disease characteristics and treatment responses were evaluated. Drug survival from systemic therapies was assessed by Kaplan–Meier analysis and multivariate regression. Results: Overall, 281 patients with a total of 407 treatment courses were identified. The overall median drug survival was 5.0 months (conventional drugs: 5.0 months vs. novel drugs [biologicals and Janus kinase inhibitors]: 17.0 months, p = 0.029). Among conventional drugs, median drug survival was numerically the highest for methotrexate (13.0 months), followed by mycophenolate mofetil (12.0 months); hydroxychloroquine (9.0 months); acitretin and cyclosporine (6.0 months each); azathioprine, dapsone, and other retinoids (5.0 months each); and finally glucocorticoids (2.0 months). Among novel drugs, median drug survival was numerically the highest in TNF‐α blockers and IL‐17 antagonists (median: 21.0 and 17.0 months, respectively), while median drug survival for Janus kinase inhibitors has not yet been reached. Altogether, the outcomes were documented in 68.6% of cases, with excellent (33.5%), partial (34.5%) or nonresponse (32.0%) in one‐third of cases each. The group of novel therapies comprising biologicals and Janus kinase inhibitors was significantly more effective than the group of conventional drugs (excellent response: 66.7%, 8/12 vs. 32.1%, 83/258; P = 0.013, χ 2 ‐test). Conclusions: In addition to glucocorticoids, cyclosporine, mycophenolate mofetil, and methotrexate (plus hydroxychloroquine), biologicals and Janus kinase inhibitors in particular seem to be therapeutic options for the treatment of mucosal LP, which is worth investigating further.
- Open Access
- 27 September 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (1) , 93-95
Severe mixed hand and generalized eczema treated with the JAK inhibitor upadacitinib
- 27 September 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (1) , 93-95
Open AccessSevere mixed hand and generalized eczema treated with the JAK inhibitor upadacitinib
- Open Access
- 10 May 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (5) , 693-695
Erste Episode einer generalisierten pustulösen Psoriasis oder akute generalisierte exanthematische Pustulose? Eine Fallstudie
- 10 May 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (5) , 693-695
Open AccessErste Episode einer generalisierten pustulösen Psoriasis oder akute generalisierte exanthematische Pustulose? Eine Fallstudie